Aurelius Systems is a San Francisco defense-technology startup building Archimedes, an autonomous, high-powered laser turret that detects, tracks and neutralizes drones in seconds for roughly the cost of electricity. Founded in 2024 by photonics veterans Michael LaFramboise and John Marmaduke, the company fuses commercial off-the-shelf hardware, advanced optics and AI-guided targeting into a compact, low-cost counter-UAS platform aimed at protecting soldiers and critical infrastructure from cheap, swarming aerial threats.
HexemBio is a New York- and Berkeley-based biotech building what it calls the first blood stem cell rejuvenation therapy. Its Synthetic Human Yolk Sac platform recreates the embryonic environment where blood stem cells first arise, temporarily placing a patient's own aged hematopoietic stem cells into that synthetic young niche before returning them by IV infusion - rather than gene-editing or chemically reprogramming the cells. The company launched publicly in April 2026 with a $10.4M seed round led by Draper Associates, holds an FDA Orphan Drug Designation for a bone-marrow-transplant program in blood cancers, and is targeting first-in-human trials in 2027.